Multidrug Resistant Tuberculosis Completed Phase 3 Trials for Linezolid (DB00601)

Also known as: MDR-TB / MDR Tuberculosis / Multidrug-Resistant Tuberculosis / Tuberculosis, Multidrug Resistant / Tuberculosis, MDR / MDR TB / Multi Drug Resistant Tuberculosis / Tuberculosis, Multidrug-Resistant / Multi-Drug Resistant Tuberculosis / TB Multi-drug Resistant / Multidrug resistant tuberculosis (disorder) / Tuberculosis / Tuberculosis (disorder) / Tuberculosis NOS / Tuberculosis NOS (disorder) / Infection TBC / Infection tuberculosis / Infection caused by Mycobacterium tuberculosis (disorder) / TB / Tuberculous (disorder) / Tuberculous (qualifier value) / Tuberculous infections

DBCOND0041129 (Multidrug Resistant Tuberculosis)Completed3 IdentifierTitlePurposeDrugs
NCT02754765Evaluating Newly Approved Drugs for Multidrug-resistant TBTreatment
NCT03086486Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant TuberculosisTreatment